Publications

Search our bibliography using the filters on the right-hand side.

Displaying 51 through 55 of 55 publications.

Earnshaw SR, Graham J, Oleen-Burkey M, Castelli-Haley J, Johnson K. Cost effectiveness of glatiramer acetate and natalizumab in relapsing-remitting multiple sclerosis. Appl Health Econ Health Policy. 2009 Jun 1;7(2):91-108.

Graham JB, Earnshaw SR, Castelli-Haley J, Oleen-Burkey M, Johnson KP. Cost-effectiveness of glatiramer acetate and natalizumab in relapsing-remitting multiple sclerosis in the presence of long-term clinical evidence. Poster presented at the 2007 ISPOR 10th Annual European Congress; October 24, 2007. [abstract] Value Health. 2007 Nov; 10(6):A381.

Bell C, Graham JB, Earnshaw S, Oleen-Burkey MK, Castelli-Haley J, Johnson K. Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data. J Manag Care Pharm. 2007 Apr 1;13(3):245-61.

Bell CF, Graham JB, Earnshaw SR, Oleen-Burkey M, Castelli-Haley J, Johnson K. Assessing the cost-effectiveness of immunomodulatory therapies for relapsing-remitting multiple sclerosis based on long-term data. Poster presented at the 2006 ISPOR 11th Annual International Meeting; May 20, 2006. Philadelphia, PA.

Bell CF, Graham JB, Earnshaw SR, Oleen-Burkey M, Castelli-Haley J, Johnson KP. Assessing the cost-effectiveness of immunomodulatory therapies for relapsing-remitting multiple sclerosis based on long-term data. Value Health. 2006 May 1;9(3):A81-2.